东北制药(000597.SZ):聘任总经理周凯兼任财务总监
格隆汇 3 月 8日丨东北制药(000597.SZ)公布,公司于2021年3月7日召开第八届董事会第四十八次会议,会议审议并通过了《关于聘任公司副总经理的议案》和《关于聘任公司总经理兼任财务总监的议案》。
根据公司业务发展需求,经总经理周凯提名,董事会提名委员会资格审核,公司董事会聘任郑伟担任公司副总经理,任期与第八届董事会期限相同。因工作变动原因,公司原任高级管理人员马卓已辞任公司财务总监职务,具体内容详见《东北制药集团股份有限公司关于财务总监因工作变动辞任的公告》(公告编号:2021-009)。
经公司董事会提名委员会资格审核,公司董事会聘任总经理周凯兼任财务总监,任期与第八届董事会期限相同。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.